Avenue Therapeutics, Inc. (ATXI): Total Assets
$2.93M
As of 2025-12-31
$1.98M
As of 2026-06-30
-24.6%
3-year compound annual growth
-2.0%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.93M | +9.7% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $2.67M | +44.4% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $1.85M | -73.0% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $6.84M | +72.9% | 2024-03-18, Balance as of period end |
| 2021-12-31 | $3.96M | +22.0% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $3.25M | -63.6% | 2022-03-25, Balance as of period end |
| 2019-12-31 | $8.91M | +97.0% | 2021-03-31, Balance as of period end |
| 2018-12-31 | $4.53M | -79.6% | 2020-03-30, Balance as of period end |
| 2017-12-31 | $22.17M | n/m | 2019-03-12, Balance as of period end |
| 2016-12-31 | $197.0K | n/a | 2018-03-01, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $2.93M | +9.7% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $81.29M | +204.1% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $12.96M | +254.9% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $7.02M | -35.2% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $8.75M | -11.7% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $48.56M | -42.4% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $58.62M | +60.0% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $10.26M | -59.9% |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $28.71M | +0.4% |
Compare ATXI, NWBO, NRXP, CPMD side by side · Screen every company in Pharmaceutical Preparations ↗